Clinical Trial Update: A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a biomarker-driven strategy with nivolumab plus ipilimumab or VEGFR TKI in first-line clear cell metastatic renal cell carcinoma has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Metastatic Renal Cell Carcinoma
• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• VEGFR TKI
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Conditions: Clear Cell Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED